Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1

Conditions

Lung Neoplasms 11Carcinoma, Non-Small-Cell Lung 6Small Cell Lung Carcinoma 5Mesothelioma 3Thymoma 2Mesothelioma, Malignant 2Hypereosinophilic Syndrome 2Dermatofibrosarcoma 2Seminoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Endometrial Stromal 1Rhabdomyosarcoma, Embryonal 1Primary Myelofibrosis 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Mastocytosis, Systemic 1Mastocytosis 1Malignant mesenchymal tumor 1Liposarcoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Mast-Cell 1Leiomyosarcoma 1

Interventions

ripretinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Imatinib Mesylate × Thoracic × Clear all
NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Novartis

Phase 2 Completed
38 enrolled
MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡